ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc (ZNTL)

3.48
-0.02
(-0.57%)
Closed 27 November 8:00AM
3.48
-0.0007
(-0.02%)
After Hours: 9:12AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
3.48
Bid
3.26
Offer
3.76
Volume
535,657
3.38 Day's Range 3.55
2.66 52 Week Range 18.07
Market Cap
Previous Close
3.50
Open
3.47
Last Trade
1
@
3.55
Last Trade Time
Financial Volume
US$ 1,873,485
VWAP
3.4975
Average Volume (3m)
2,148,137
Shares Outstanding
71,265,400
Dividend Yield
-
PE Ratio
-0.85
Earnings Per Share (EPS)
-4.1
Revenue
-
Net Profit
-292.19M

About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets a... Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Zentalis Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZNTL. The last closing price for Zentalis Pharmaceuticals was US$3.50. Over the last year, Zentalis Pharmaceuticals shares have traded in a share price range of US$ 2.66 to US$ 18.07.

Zentalis Pharmaceuticals currently has 71,265,400 shares in issue. The market capitalisation of Zentalis Pharmaceuticals is US$249.43 million. Zentalis Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.85.

ZNTL Latest News

Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib

Julie Eastland appointed Chief Executive Officer, President and Director Ingmar Bruns, M.D., appointed Chief Medical Officer Scott Myers appointed to the Board of Directors as Chairperson SAN...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, Sept. 16, 2024 NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.4213.72549019613.063.62.911203113.19610662CS
40.6522.96819787992.834.442.6615961753.40775654CS
120.061.754385964913.425.442.6621481373.55761693CS
26-8.24-70.307167235511.72132.6617638014.09329961CS
52-7.24-67.537313432810.7218.072.6612809766.97857128CS
156-72.68-95.430672268976.1685.952.6687858216.80076025CS
260-21.21-85.905224787424.6987.192.6665774221.46805496CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PSTXPoseida Therapeutics Inc
US$ 9.38
(227.97%)
30.14M
IMGCIMG Inc
US$ 1.615
(156.35%)
114.51M
IDAIT Stamp Inc
US$ 0.364
(102.22%)
560.18M
PGHLPrimega Group Holdings Ltd
US$ 20.95
(98.77%)
2.89M
TOYOTOYO Company Ltd
US$ 5.41
(86.55%)
49.09M
ALECAlector Inc
US$ 2.575
(-34.97%)
8.13M
ABVEAbove Food Ingredients Inc
US$ 0.5338
(-34.42%)
1.66M
LGCLLucas GC Ltd
US$ 0.7511
(-33.53%)
2.48M
ADDColor Star Technology Company Ltd
US$ 4.19
(-31.87%)
205.78k
LESLLeslies Inc
US$ 2.445
(-30.34%)
24.55M
IDAIT Stamp Inc
US$ 0.364
(102.22%)
560.18M
ELABElevai Labs Inc
US$ 0.01255
(-21.07%)
325.82M
NVDANVIDIA Corporation
US$ 136.92
(0.66%)
190.3M
RGTIRigetti Computing Inc
US$ 2.195
(-20.18%)
126.72M
IMGCIMG Inc
US$ 1.615
(156.35%)
114.51M

ZNTL Discussion

View Posts
Awl416 Awl416 2 months ago
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
👍️0
glenn1919 glenn1919 2 months ago
ZNTL.......................................https://stockcharts.com/h-sc/ui?s=ZNTL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 months ago
ZNTL under $4
👍️0
ANTADOG ANTADOG 4 years ago
We managed to get a new 26 week high and a reset around 46 bucks, will be interesting to see where it goes next, chartwise it's up, imo of course, ANT
👍️0
ANTADOG ANTADOG 4 years ago
Added some 46's , nice chart reset, ANT
👍️0
ANTADOG ANTADOG 4 years ago
55.12~~ looks like this puppy is on it's way for a new 52 week high, my target here is 100 bucks because of the very promising pipeline , fyi imo ANT
👍️0
ANTADOG ANTADOG 4 years ago
NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Ahmed Samatar, Ph.D., Senior Vice President of Oncology Research at Zentalis, will present preclinical data on ZN-c5 at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting II taking place June 22-24th.

The preclinical data demonstrated that ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, had antitumor activity in human tumor breast cancer xenograft models. ZN-c5 also displayed excellent oral bioavailability across several preclinical species. ZN-c5 is currently being evaluated in a Phase 1/2 clinical trial in patients with ER+/HER2- advanced or metastatic breast cancer both as a single agent and in combination studies.
👍️0
ANTADOG ANTADOG 4 years ago
NEW YORK and SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.
fyi ANT
👍️0
ANTADOG ANTADOG 4 years ago
New 52 week high at 52.09, i luv it, ANT
👍️0
ANTADOG ANTADOG 5 years ago
Cash Position: As of March 31, 2020, Zentalis had cash and cash equivalents of $63.7 million. We expect that the Company’s existing cash and cash equivalents, together with the net proceeds of $172.4 million from the IPO, will enable the Company to fund its operating expenses and capital expenditure requirements into 2022.
fyi ANT
👍️0
ANTADOG ANTADOG 5 years ago
Chart is pretty fresh here, anyway, i see a trendline curlin' up already (10ma on the daily at 35.9), fyi ANT
👍️0
ANTADOG ANTADOG 5 years ago
promisin' co, interestin' pipeline, touched new 52 week high today (42.83), enormous spread every now and then, fyi ANT
👍️0
crudeoil24 crudeoil24 5 years ago
ZNTL opens @ 25.20 >
👍️0
crudeoil24 crudeoil24 5 years ago
Zentalis Pharma Upsized IPO Prices at High End of Range >ZNTL
6:08 am ET April 3, 2020 (Dow Jones) Print
By Colin Kellaher

Zentalis Pharmaceuticals Inc. said its upsized initial public offering of 9.18 million shares was priced at $18 each, the high end of the expected range.

The New York clinical-stage cancer biopharmaceutical company earlier this week said it expected to sell 7.65 million shares at $16 to $18 apiece.

Zentalis said it expects gross proceeds of $165.2 million from the IPO, adding that it has granted the underwriters an option to buy up to 1.38 million additional shares.

Zentalis previously said it will use proceeds from the offering to advance the development of its drug candidates.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 03, 2020 06:08 ET (10:08 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
👍️0
crudeoil24 crudeoil24 5 years ago
Zentalis Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
👍️0